Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide’s favourable hepatic profile in patients with Metabolic Dysfunction-associated…
